The proposed book is intended as a primer, giving students and newcomers to the field an opportunity to learn about the breadth of the CNS drug discovery and the various stages in the drug discovery process from evaluating drugs for their efficacy and safety in animals and humans to identifying future drug targets. It will be heavily informed by recent experimental evidence and the impediments in the pipeline of drug discovery. It will draw on the attempts to develop translational research strategies in CNS drug development. It will highlight the emergence of a critical path for the development of new CNS drugs as identified by the FDA in their report on the slowdown in the development new chemical entities across the disease spectrum. Section I will briefly introduce the principal CNS disease states, how they are diagnosed and classified, the current theories about their aetiology, as well as a description of the pharmacological targets currently used to treat these diseases. In Section II, chapters will be devoted to each of the key steps in the drug development process, starting with the discovery and test-tube screening, and finishing with the post-marketing surveillance stage. Section III will examine the drug targets of the future, the challenges facing their development and will discuss genetic possibilities of treating CNS diseases. Examples of specific drugs will be used throughout the book to produce a coherent picture of the drug development process. Primary reasons for drug failure will be given for each stage in order toillustrate potential pitfalls and obstacles.
- ISBN: 978-0-470-51979-0
- Editorial: John Wiley & Sons
- Encuadernacion: Cartoné
- Páginas: 328
- Fecha Publicación: 08/01/2010
- Nº Volúmenes: 1
- Idioma: Inglés